| Basics |
VistaGen Therapeutics, Inc.
VistaGen Therapeutics Inc is a clinical-stage biopharmaceutical company that develops and commercializes product candidates for patients with central nervous system diseases. Its product AV-101 is currently being evaluated in a Phase 2 monotherapy study.
|
| IPO Date: |
July 1, 2011 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$171.02M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.09 | 4.03%
|
| Avg Daily Range (30 D): |
$0.19 | 4.51%
|
| Avg Daily Range (90 D): |
$0.14 | 3.67%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.36M |
| Avg Daily Volume (30 D): |
.7M |
| Avg Daily Volume (90 D): |
.51M |
| Trade Size |
| Avg Trade Size (Sh.): |
425 |
| Avg Trade Size (Sh.) (30 D): |
156 |
| Avg Trade Size (Sh.) (90 D): |
159 |
| Institutional Trades |
| Total Inst.Trades: |
84 |
| Avg Inst. Trade: |
$2.29M |
| Avg Inst. Trade (30 D): |
$1.93M |
| Avg Inst. Trade (90 D): |
$5.49M |
| Avg Inst. Trade Volume: |
.22M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.82M |
| Avg Closing Trade (30 D): |
$.76M |
| Avg Closing Trade (90 D): |
$.76M |
| Avg Closing Volume: |
147.97K |
|
|
| Financials |
| |
TTM |
Q2 2026 |
Q1 2026 |
|
Basic EPS
|
$-1.92
|
$-.54
|
$-.47
|
|
Diluted EPS
|
$-1.92
|
$-.54
|
$-.47
|
|
Revenue
|
$ .72M
|
$ .26M
|
$ .24M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -62.24M
|
$ -19.42M
|
$ -15.1M
|
|
Operating Income / Loss
|
$ -65.47M
|
$ -20.05M
|
$ -15.8M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -21.46M
|
$ 13.8M
|
$ -18.15M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Jun 07, 2023:
1:30
|
|
Aug 14, 2014:
1:20
|
|
Jun 10, 2011:
2:1
|
|
|
|
